연구성과로 돌아가기
2020 연구성과 (39 / 270)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| WoS | SCOPUS | Document Type | Document Title | Abstract | Authors | Affiliation | ResearcherID (WoS) | AuthorsID (SCOPUS) | Author Email(s) | Journal Name | JCR Abbreviation | ISSN | eISSN | Volume | Issue | WoS Edition | WoS Category | JCR Year | IF | JCR (%) | FWCI | FWCI Update Date | WoS Citation | SCOPUS Citation | Keywords (WoS) | KeywordsPlus (WoS) | Keywords (SCOPUS) | KeywordsPlus (SCOPUS) | Language | Publication Stage | Publication Year | Publication Date | DOI | JCR Link | DOI Link | WOS Link | SCOPUS Link |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ○ | ○ | Article | Changes in High Density Lipoprotein Cholesterol and Risks of Cardiovascular Events: A Post Hoc Analysis from the PICASSO Trial | Background and purpose Whether pharmacologically altered high-density lipoprotein cholesterol (HDL-C) affects the risk of cardiovascular events is unknown. Recently, we have reported the Prevention of Cardiovascular Events in Asian Patients with Ischaemic Stroke at High Risk of Cerebral Haemorrhage (PICASSO) trial that demonstrated the non-inferiority of cilostazol to aspirin and superiority of probucol to non-probucol for cardiovascular prevention in ischemic stroke patients (clinicaltrials.gov: NCT01013532). We aimed to determine whether on-treatment HDL-C changes by cilostazol and probucol influence the treatment effect of each study medication during the PICASSO study. Methods Of the 1,534 randomized patients, 1,373 (89.5%) with baseline cholesterol parameters were analyzed. Efficacy endpoint was the composite of stroke, myocardial infarction, and cardiovascular death. Cox proportional hazards regression analysis examined an interaction between the treatment effect and changes in HDL-C levels from randomization to 1 month for each study arm. Results One-month post-randomization mean HDL-C level was significantly higher in the cilostazol group than in the aspirin group (1.08 mmol/L vs. 1.00 mmol/L, P<0.001). The mean HDL-C level was significantly lower in the probucol group than in the non-probucol group (0.86 mmol/L vs. 1.22 mmol/L, P<0.001). These trends persisted throughout the study. In both study arms, no significant interaction was observed between HDL-C changes and the assigned treatment regarding the risk of the efficacy endpoint. Conclusions Despite significant HDL-C changes, the effects of cilostazol and probucol treatment on the risk of cardiovascular events were insignificant Pharmacologically altered HDL-C levels may not be reliable prognostic markers for cardiovascular risk. | Lee, Eun-Jae; Kwon, Sun U.; Park, Jong-Ho; Kim, Yong-Jae; Hong, Keun-Sik; Yu, Sungwook; Hwang, Yang-Ha; Lee, Ji Sung; Lee, Juneyoung; Rha, Joung-Ho; Heo, Sung Hyuk; Ahn, Sung Hwan; Seo, Woo-Keun; Park, Jong-Moo; Lee, Ju-Hun; Kwon, Jee-Hyun; Sohn, Sung-Il; Jung, Jin-Man; Kim, Hahn Young; Kim, Eung-Gyu; Kim, Sung Hun; Cha, Jae-Kwan; Park, Man-Seok; Nam, Hyo Suk; Kang, Dong-Wha | Univ Ulsan, Coll Med, Asan Med Ctr, Dept Neurol, 88 Olymp Ro, Seoul 05505, South Korea; Hanyang Univ, Coll Med, Myongji Hosp, Dept Neurol, Goyang, South Korea; Catholic Univ Korea, Coll Med, Eunpyeong St Marys Hosp, Dept Neurol, Seoul, South Korea; Inje Univ, Coll Med, Ilsan Paik Hosp, Dept Neurol, Goyang, South Korea; Korea Univ, Coll Med, Anam Hosp, Dept Neurol, Seoul, South Korea; Kyungpook Natl Univ, Sch Med, Kyungpook Natl Univ Hosp, Dept Neurol, Daegu, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Clin Res Ctr, Seoul, South Korea; Korea Univ, Dept Biostat, Seoul, South Korea; Inha Univ Hosp, Dept Neurol, Incheon, South Korea; Kyung Hee Univ, Dept Neurol, Med Ctr, Seoul, South Korea; Chosun Univ, Coll Med, Dept Neurol, Chosun Univ Hosp, Gwangju, South Korea; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurol, Seoul, South Korea; Eulji Univ, Sch Med, Eulji Gen Hosp, Dept Neurol, Seoul, South Korea; Hallym Univ, Kangdong Sacred Heart Hosp, Coll Med, Dept Neurol, Seoul, South Korea; Univ Ulsan, Coll Med, Ulsan Univ Hosp, Dept Neurol, Ulsan, South Korea; Keimyung Univ, Sch Med, Dongsan Med Ctr, Dept Neurol, Daegu, South Korea; Korea Univ, Coll Med, Ansan Hosp, Dept Neurol, Ansan, South Korea; Konkuk Univ, Sch Med, Dept Neurol, Seoul, South Korea; Inje Univ, Coll Med, Busan Paik Hosp, Dept Neurol, Busan, South Korea; Kangwon Natl Univ, Sch Med, Kangwon Natl Univ Hosp, Dept Neurol, Chunchon, South Korea; Dong A Univ, Coll Med, Dong A Univ Hosp, Dept Neurol, Busan, South Korea; Chonnam Natl Univ, Sch Med, Dept Neurol, Gwangju, South Korea; Yonsei Univ, Coll Med, Dept Neurol, Seoul, South Korea | HWANG, Yang-Ha/F-3068-2013; Kim, Sang-Gyu/T-5925-2017; Heo, Sung/P-3529-2019; LEE, HYUN/D-6482-2016; Lee, Sang-Hwa/ISU-5166-2023; Jung, Jin-Man/LJL-8037-2024; Lee, Ha/ABF-6005-2020; Kim, Yong-Jae/JQW-5758-2023 | 35409781500; 7402624264; 55716977200; 55865497600; 7402515553; 56144716300; 7402311308; 57217244570; 34667876400; 6701393879; 18835720200; 57200401172; 22981667600; 8407334400; 36243671200; 26661940800; 36479287000; 15755814800; 15741139400; 35169942100; 57206875764; 7202455743; 7404490852; 57216373862; 7402889386 | sukwon@amc.seoul.kr; | JOURNAL OF STROKE | J STROKE | 2287-6391 | 2287-6405 | 22 | 1 | SCIE | CLINICAL NEUROLOGY;PERIPHERAL VASCULAR DISEASE | 2020 | 6.967 | 10.3 | 0.08 | 2025-06-25 | 4 | 2 | Cholesterol, HDL; Secondary prevention; Cilostazol; Probucol; Cholesterol ester transfer proteins | CEREBRAL-HEMORRHAGE PICASSO; PHOSPHODIESTERASE INHIBITOR; CAROTID ATHEROSCLEROSIS; HDL CHOLESTEROL; ISCHEMIC-STROKE; STATIN THERAPY; PROBUCOL; PREVENTION; DISEASE; TRIGLYCERIDES | Cholesterol; Cholesterol ester transfer proteins; Cilostazol; HDL; Probucol; Secondary prevention | acetylsalicylic acid; cilostazol; high density lipoprotein cholesterol; hydroxymethylglutaryl coenzyme A reductase inhibitor; probucol; aged; Article; cardiovascular mortality; cardiovascular risk; cerebrovascular accident; cholesterol blood level; clinical outcome; controlled study; double blind procedure; drug efficacy; factorial design; female; follow up; heart infarction; human; major clinical study; male; multicenter study; outcome assessment; post hoc analysis; randomized controlled trial; regression analysis | English | 2020 | 2020-01 | 10.5853/jos.2019.02551 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Characteristics of linezolid-resistant Enterococcus faecalis isolates from broiler breeder farms | Linezolid is an oxazolidinone class antibiotic used for treatment infections caused by various multidrug-resistant gram-positive pathogens including enterococci. However, recently, linezolid-resistant isolates in animals are considered as a human health hazard. In a broiler operation system, antimicrobial resistance can be transferred to the environment and commercial broiler via the fecal-oral route. Therefore, this study was conducted to investigate the prevalence and characteristics of linezolid-resistant Enterococcus faecalis (E. faecalis) from broiler parent stock in a broiler operation system. Among 297 E. faecalis isolates from 85 flocks in 8 broiler breeder farms, the prevalence of chloramphenicol- and linezolid-resistant isolates was 0 to 12.1% and 0 to 8.0%, respectively; however, there were no significant differences between farms. Therefore, a total of 14 (4.7%) chloramphenicol- and/or linezolid-resistant E. faecalis showed resistance to 7 or more antimicrobial classes. The drug-resistance gene optrA, which can confer resistance to linezolid, tedizolid, and phenicols, was found in 8 (2.69%) isolates, and 7 (2.36%) of the 8 optrA-positive isolates co-carried the phenicol exporter gene fexA. However, E. faecalis isolates from 3 of 8 broiler breeder farms only carried the optrA and/or fexA genes. As linezolid is one of the last antimicrobial treatments of choice for multidrug-resistant gram-positive pathogens including E. faecalis, the presence of antibiotic-resistant E. faecalis in broiler breeder farms should be monitored to prevent the introduction of linezolid-resistant strains to the food chain. | Yoon, Sunghyun; Kim, Yeong Bin; Seo, Kwang Won; Ha, Jong Su; Noh, Eun Bi; Lee, Young Ju | Kyungpook Natl Univ, Coll Vet Med, Daegu 41566, South Korea; Kyungpook Natl Univ, Zoonoses Res Inst, Daegu 41566, South Korea; Mississippi State Univ, Coll Vet Med, Dept Basic Sci, Mississippi State, MS 39762 USA; Samhwa GPS Breeding Agr Inc, Qual Management Dept, Hongseong 32291, South Korea | Yoon, Sunghyun/AAL-4806-2021 | 57216037473; 57200044764; 57203233812; 56180548400; 57209844683; 56612134500 | youngju@knu.ac.kr; | POULTRY SCIENCE | POULTRY SCI | 1525-3171 | 99 | 11 | SCIE | AGRICULTURE, DAIRY & ANIMAL SCIENCE | 2020 | 3.352 | 10.3 | 1.71 | 2025-06-25 | 15 | 17 | linezolid-resistant; optrA; broiler breeder; Enterococcus faecalis; antimicrobial resistance | 23S RIBOSOMAL-RNA; ANTIMICROBIAL RESISTANCE; ANNUAL APPRAISAL; GENE OPTRA; FAECIUM; OXAZOLIDINONE; CFR; CHLORAMPHENICOL; FLORFENICOL; INFECTIONS | antimicrobial resistance; broiler breeder; Enterococcus faecalis; linezolid-resistant; optrA | Animals; Anti-Bacterial Agents; Chickens; Drug Resistance, Bacterial; Enterococcus faecalis; Gram-Positive Bacterial Infections; Linezolid; Microbial Sensitivity Tests; Poultry Diseases; antiinfective agent; linezolid; animal; antibiotic resistance; bird disease; chicken; drug effect; Enterococcus faecalis; genetics; Gram positive infection; microbial sensitivity test; microbiology; veterinary medicine | English | 2020 | 2020-11 | 10.1016/j.psj.2020.06.087 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Combined effects of sous-vide cooking conditions on meat and sensory quality characteristics of chicken breast meat | This study investigated the combined effects of cooking temperature and time on the meat and eating quality characteristics of the sous-vide chicken breast. For the control group, chicken breast samples were cooked in a convection oven until the internal temperature reached 710 degrees C. Each sample for sous-vide cooking was vacuum packaged and then cooked under continuous thermocontrolled conditions in a water bath at 6 combinations of cooking temperature (60 and 700 degrees C) and time (1, 2, and 3 h). Sous-vide cooked chicken meat at 60 degrees C for 1 h (SV60-1h) showed lower cooking loss (6.58 vs. 26.5%, P < 0.05), Warner-Bratzler shear force (21.7 vs. 29.1 N, P < 0.05), and hardness (9.40 vs. 17.3 N, P < 0.05) than meat cooked by conventional oven. Similar to the objective tenderness parameters, cooked chicken meat from the SV60 treatments for all cooking times showed higher scores in all the tenderness attri-butes than the control group (P < 0.05). However, a higher flavor intensity was observed in the SV70-3h and control groups than in the SV60 treatments (P < 0.05). Owing to a lesser developed flavor in chicken meat from the SV60-1h treatment, the SV60-2h and 3h treatments were assigned a higher acceptability rating for overall impression (P < 0.05). Therefore, cooking temperature and time of sous-vide significantly influenced the physicochemical and palatability characteristics of chicken breast. In this study, the optimum conditions for the sous-vide chicken breast are to continuously cook at 600 degrees C for 2 to 3 h to improve sensory quality characteristics without reducing the water-holding capacity. | Park, C. H.; Lee, B.; Oh, E.; Kim, Y. S.; Choi, Y. M. | Korea Univ, Dept Integrated Biomed & Life Sci, Seoul, South Korea; Daejeon Hlth Inst Technol, Dept Hotel & Food Serv Culinary Art, Daejeon, South Korea; Kyungpook Natl Univ, Dept Anim Sci, Sangju, South Korea | Kim, Chang Gon/IAP-6721-2023 | 57216440160; 57218130871; 57203065295; 57196173426; 57226673843 | kteresa@korea.ac.kr;ymchoi1@knu.ac.kr; | POULTRY SCIENCE | POULTRY SCI | 1525-3171 | 99 | 6 | SCIE | AGRICULTURE, DAIRY & ANIMAL SCIENCE | 2020 | 3.352 | 10.3 | 6.55 | 2025-06-25 | 70 | 74 | sous-vide; cooking condition; meat quality; sensory quality; chicken breast | PROTEINS; COLOR; HEAT | chicken breast; cooking condition; meat quality; sensory quality; sous-vide | Animals; Chickens; Cooking; Meat; Pectoralis Muscles; Taste; Temperature; animal; chicken; cooking; meat; pectoral muscle; physiology; procedures; taste; temperature | English | 2020 | 2020-06 | 10.1016/j.psj.2020.03.004 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin | Since sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced blood glucose level by inhibiting renal tubular glucose reabsorption mediated by SGLT2, we aimed to investigate the pharmacokinetics and kidney distribution of DWP16001, a novel SGLT2 inhibitor, and to compare these properties with those of dapagliflozin and ipragliflozin, representative SGLT2 inhibitors. The plasma exposure of DWP16001 was comparable with that of ipragliflozin but higher than that of dapagliflozin. DWP16001 showed the highest kidney distribution among three SGLT2 inhibitors when expressed as an area under curve (AUC) ratio of kidney to plasma (85.0 +/- 16.1 for DWP16001, 64.6 +/- 31.8 for dapagliflozin and 38.4 +/- 5.3 for ipragliflozin). The organic anion transporter-mediated kidney uptake of DWP16001 could be partly attributed to the highest kidney uptake. Additionally, DWP16001 had the lowest half-maximal inhibitory concentration (IC50) to SGLT2, a target transporter (0.8 +/- 0.3 nM for DWP16001, 1.6 +/- 0.3 nM for dapagliflozin, and 8.9 +/- 1.7 nM for ipragliflozin). The inhibition mode of DWP16001 on SGLT2 was reversible and competitive, but the recovery of the SGLT2 inhibition after the removal of SGLT2 inhibitors in CHO cells overexpressing SGLT2 was retained with DWP16001, which is not the case with dapagliflozin and ipragliflozin. In conclusion, selective and competitive SGLT2 inhibition of DWP16001 could potentiate the efficacy of DWP16001 in coordination with the higher kidney distribution and retained SGLT2 inhibition of DWP16001 relative to dapagliflozin and ipragliflozin. | Choi, Min-Koo; Nam, So Jeong; Ji, Hye-Young; Park, Mi Jie; Choi, Ji-Soo; Song, Im-Sook | Dankook Univ, Coll Pharm, Cheonan 31116, South Korea; Kyungpook Natl Univ, Coll Pharm, Daegu 41566, South Korea; Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Daegu 41566, South Korea; Daewoong Pharmaceut, Life Sci Inst, Yongin 17028, Gyeonggido, South Korea | 8695781400; 57195054110; 57215682552; 57215695382; 57215689019; 7201564500 | minkoochoi@dankook.ac.kr;goddns159@nate.com;hychi138@daewoong.co.kr;mjpark201@daewoong.co.kr;jschoi172@daewoong.co.kr;isssong@knu.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 12 | 3 | SCIE | PHARMACOLOGY & PHARMACY | 2020 | 6.321 | 10.3 | 2.47 | 2025-06-25 | 34 | 38 | sodium-glucose cotransporter 2 (SGLT2) inhibitors; DWP16001; kidney distribution; inhibition mode | DRUG-DRUG INTERACTIONS; SGLT2 INHIBITOR; TRANSPORT; POTENT | DWP16001; Inhibition mode; Kidney distribution; Sodium-glucose cotransporter 2 (SGLT2) inhibitors | dapagliflozin; dwp 16001; ipragliflozin; organic anion transporter 1; organic anion transporter 3; sodium glucose cotransporter 1; sodium glucose cotransporter 2; sodium glucose cotransporter 2 inhibitor; suglat; unclassified drug; animal cell; animal experiment; area under the curve; Article; CHO cell line; controlled study; drug blood level; drug distribution; drug protein binding; drug uptake; enzyme specificity; HEK293 cell line; human; human cell; IC50; liquid chromatography-mass spectrometry; male; maximum plasma concentration; mouse; nonhuman; pharmacodynamics; time to maximum plasma concentration | English | 2020 | 2020-03 | 10.3390/pharmaceutics12030268 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Enhanced Intestinal Absorption and Pharmacokinetic Modulation of Berberine and Its Metabolites through the Inhibition of P-Glycoprotein and Intestinal Metabolism in Rats Using a Berberine Mixed Micelle Formulation | We aimed to develop a berberine formulation to enhance the intestinal absorption and plasma concentrations of berberine through the inhibition of P-glycoprotein (P-gp)-mediated efflux and the intestinal metabolism of berberine in rats. We used pluronic P85 (P85) and tween 80, which have the potential to inhibit P-gp and cytochrome P450s (i.e., CYP1A2, 2C9, 2C19, 2D6, and 3A4). A berberine-loaded mixed micelle formulation with ratios of berberine: P85: tween 80 of 1:5:0.5 (w/w/w) was developed. This berberine mixed micelle formulation had a mean size of 12 nm and increased the cellular accumulation of digoxin via P-gp inhibition. It also inhibited berberine metabolism in rat intestinal microsomes, without significant cytotoxicity, up to a berberine concentration of 100 mu M. Next, we compared the pharmacokinetics of berberine and its major metabolites in rat plasma following the oral administration of the berberine formulation (50 mg/kg) in rats with the oral administration of berberine alone (50 mg/kg). The plasma exposure of berberine was significantly greater in rats administered the berberine formulation compared to rats administered only berberine, which could be attributed to the increased berberine absorption by inhibiting the P-gp-mediated berberine efflux and intestinal berberine metabolism by berberine formulation. In conclusion, we successfully prepared berberine mixed micelle formulation using P85 and tween 80 that has inhibitory potential for P-gp and CYPs (CYP2C19, 2D6, and 3A4) and increased the berberine plasma exposure. Therefore, a mixed micelle formulation strategy with P85 and tween 80 for drugs with high intestinal first-pass effects could be applied to increase the oral absorption and plasma concentrations of the drugs. | Kwon, Mihwa; Lim, Dong Yu; Lee, Chul Haeng; Jeon, Ji-Hyeon; Choi, Min-Koo; Song, Im-Sook | Kyungpook Natl Univ, Coll Pharm, Daegu 41566, South Korea; Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Daegu 41566, South Korea; Dankook Univ, Coll Pharm, Cheonan 31116, South Korea | 55964714000; 57219057824; 57219051827; 57204685946; 8695781400; 7201564500 | mihwa_k@naver.com;twins3639@naver.com;hang1130@naver.com;kei7016@naver.com;minkoochoi@dankook.ac.kr;isssong@knu.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 12 | 9 | SCIE | PHARMACOLOGY & PHARMACY | 2020 | 6.321 | 10.3 | 4.26 | 2025-06-25 | 59 | 62 | berberine; pluronic P85 (P85); tween 80; pharmacokinetics; P-gp inhibition; CYP inhibition | PLURONIC BLOCK-COPOLYMERS; ORAL BIOAVAILABILITY; DRUG; EFFLUX; TRANSPORT; IDENTIFICATION; MECHANISM; DELIVERY; INVOLVEMENT; PERMEATION | Berberine; CYP inhibition; P-gp inhibition; Pharmacokinetics; Pluronic P85 (P85); Tween 80 | ABC transporter subfamily B; berberine; beroline; cytochrome P450 1A2; cytochrome P450 2C19; cytochrome P450 2C9; cytochrome P450 2D6; cytochrome P450 3A4; digoxin; drug metabolite; poloxamer; polysorbate 80; thalifendine; animal cell; animal experiment; area under the curve; Article; Caco-2 cell line; controlled study; drug absorption; drug accumulation; drug bioavailability; drug blood level; drug cytotoxicity; drug exposure; drug formulation; drug metabolism; drug penetration; drug solubility; enzyme activity; first pass effect; human; human cell; IC50; in vitro study; in vivo study; intestine absorption; liver microsome; LLC-PK1 cell line; male; maximum plasma concentration; micelle; nonhuman; particle size; rat; time to maximum plasma concentration | English | 2020 | 2020-09 | 10.3390/pharmaceutics12090882 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Evaluation of the Pharmacokinetic Drug-Drug Interaction between Micronized Fenofibrate and Pitavastatin in Healthy Volunteers | Dyslipidemia is a major risk factor for development of atherosclerosis and cardiovascular disease (CVD). Effective lipid-lowering therapies has led to CVD risk reduction. This study evaluated the possible pharmacokinetic interactions between fenofibrate, a peroxisome proliferators-activated receptors alpha agonist, and pitavastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A reductase inhibitor, in healthy Korean subjects. The study design was an open-label, randomized, multiple-dose, three-period, and six-sequence crossover study with a 10-day washout in 24 healthy volunteers. It had three treatments: 160 mg of micronized fenofibrate once daily for 5 days; 2 mg of pitavastatin once daily for 5 days; and 160 mg of micronized fenofibrate with 2 mg of pitavastatin for 5 days. Serial blood samples were collected at scheduled intervals for up to 48 h after the last dose in each period to determine the steady-state pharmacokinetics of both drugs. Plasma concentrations of fenofibric acid and pitavastatin were measured using a validated high-performance liquid chromatography with the tandem mass spectrometry method. A total of 24 subjects completed the study. Pitavastatin, when co-administered with micronized fenofibrate, had no effect on the C-max,C-ss and AUC(tau,ss) of fenofibric acid. The C-max,C-ss and AUC(tau,ss) of pitavastatin were increased by 36% and 12%, respectively, when co-administered with fenofibrate. Combined treatment with pitavastatin and micronized fenofibrate was generally well tolerated without serious adverse events. Our results demonstrated no clinically significant pharmacokinetic interactions between micronized fenofibrate and pitavastatin when 160 mg of micronized fenofibrate and 2 mg of pitavastatin are co-administered. The treatments were well tolerated during the study, with no serious adverse events. | Lee, Hae Won; Kang, Woo Youl; Jung, Wookjae; Gwon, Mi-Ri; Cho, Kyunghee; Yang, Dong Heon; Yoon, Young-Ran; Seong, Sook Jin | Kyungpook Natl Univ, Sch Med, Dept Mol Med, Daegu 41566, South Korea; Kyungpook Natl Univ Hosp, Dept Clin Pharmacol, Daegu 41566, South Korea; Biocore Co Ltd, Analyt Res Div, Seoul 08511, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Div Cardiol, Daegu 41944, South Korea | Yoon, Young-Ran/GLT-0172-2022 | 57202973823; 56816263900; 57218206353; 56035800800; 57211130109; 35277423400; 14629744500; 57211130049 | haewonbbc@gmail.com;youwoo2@nate.com;wookjaejung@nate.com;miri.gwon@gmail.com;khcho@bio-core.com;ddhyang@knu.ac.kr;yry@knu.ac.kr;wintersj@knu.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 12 | 9 | SCIE | PHARMACOLOGY & PHARMACY | 2020 | 6.321 | 10.3 | 0.3 | 2025-06-25 | 6 | 8 | micronized fenofibrate; pharmacokinetics; drug-drug interaction; pitavastatin; safety | HUMAN PLASMA; MANAGEMENT; EFFICACY; DYSLIPIDEMIA; HYPERCHOLESTEROLEMIA; ATHEROSCLEROSIS; RECOMMENDATIONS; TOLERABILITY; STATINS; SAFETY | Drug-drug interaction; Micronized fenofibrate; Pharmacokinetics; Pitavastatin; Safety | fenofibrate; lipilfen; pitavastatin; adult; area under the curve; Article; backache; blood sampling; controlled study; diarrhea; drug blood level; drug clearance; drug elimination; drug half life; drug safety; drug screening; drug tolerability; hematuria; high performance liquid chromatography; human; human experiment; hypertransaminasemia; hyperuricemia; Korean (people); male; maximum concentration; myalgia; normal human; pharmacokinetic parameters; plasma concentration-time curve; randomized controlled trial; steady state; tandem mass spectrometry; time to maximum plasma concentration; treatment duration; volunteer | English | 2020 | 2020-09 | 10.3390/pharmaceutics12090869 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Review | Extracellular Vesicle- and Extracellular Vesicle Mimetics-Based Drug Delivery Systems: New Perspectives, Challenges, and Clinical Developments | Extracellular vesicles (EVs) are small membrane-based nanovesicles naturally released from cells. Extracellular vesicles mimetics (EVMs) are artificial vesicles engineered from cells or in combination with lipid materials, and they mimic certain characteristics of EVs. As such, EVs facilitate intracellular communication by carrying and delivering biological materials, such as proteins, lipids, and nucleic acids, and they have been found to find organ tropism in preclinical studies. Because of their native structure and characteristics, they are considered promising drug carriers for future clinical use. This review outlines the origin and composition of natural EVs and EVM engineering and internalization. It then details different loading approaches, with examples of the drug delivery of therapeutic molecules. In addition, the advantages and disadvantages of loading drugs into EVs or EVMs as a drug delivery system are discussed. Finally, the advantages of EVMs over EVs and the future clinical translation of EVM-based drug delivery platforms are outlined. | Gangadaran, Prakash; Ahn, Byeong-Cheol | Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Nucl Med, Daegu 41944, South Korea; Kyungpook Natl Univ, Sch Med, Dept Biomed Sci, BK21 Plus KNU Biomed Convergence Program, Daegu 41944, South Korea | ; Gangadaran, Prakash/AAV-3102-2021 | 54393130400; 7202791511 | prakashg@knu.ac.kr;abc2000@knu.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 12 | 5 | SCIE | PHARMACOLOGY & PHARMACY | 2020 | 6.321 | 10.3 | 6.83 | 2025-06-25 | 95 | 92 | extracellular vesicles; extracellular vesicle mimetics; pharmaceuticals; drug loading; delivery | MESENCHYMAL STEM-CELLS; MILK-DERIVED EXOSOMES; IN-VITRO; TRANSFERRIN RECEPTOR; MEMBRANE-VESICLES; MICROVESICLES; NANOVESICLES; PACLITAXEL; APOPTOSIS; BIOMARKERS | Delivery; Drug loading; Extracellular vesicle mimetics; Extracellular vesicles; Pharmaceuticals | catalase; celastrol; curcumin; docetaxel; dopamine; doxorubicin; h19 smart silencer; long untranslated RNA; messenger RNA; microRNA; Myc protein; Nedd4 family interacting protein 1; paclitaxel; porphyrin; protein; signal regulatory protein alpha; small interfering RNA; unclassified drug; vasculotropin; withaferin A; antiinflammatory activity; Article; biogenesis; cancer inhibition; cell engineering; cell structure; diabetes mellitus; drug delivery system; drug mechanism; electroporation; exosome; freeze thawing; genetic engineering; human; incubation time; inflammation; internalization; malignant neoplasm; neuroprotection; nonhuman; Parkinson disease; saponification; ultrasound | English | 2020 | 2020-05 | 10.3390/pharmaceutics12050442 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Fabrication of Intragastric Floating, Controlled Release 3D Printed Theophylline Tablets Using Hot-Melt Extrusion and Fused Deposition Modeling | This work presents a novel approach for producing gastro-retentive floating tablets (GRFT) by coupling hot-melt extrusion (HME) and fused deposition three-dimensional printing (3DP). Filaments containing theophylline (THEO) within a hydroxypropyl cellulose (HPC) matrix were prepared using HME. 3DP tablets with different infill percentages and shell thickness were developed and evaluated to determine their drug content, floating behavior, dissolution, and physicochemical properties. The dissolution studies revealed a relationship between the infill percentage/shell thickness and the drug release behavior of the 3DP tablets. All the developed GRFTs possessed the ability to float for 10 h and exhibited zero-order release kinetics. The drug release could be described by the Peppas-Sahlin model, as a combination of Fickian diffusion and swelling mechanism. Drug crystallinity was found unaltered throughout the process. 3DP coupled with HME, could be an effective blueprint to produce controlled-release GRFTs, providing the advantage of simplicity and versatility compared to the conventional methods. | Giri, Bhupendra Raj; Song, Eon Soo; Kwon, Jaewook; Lee, Ju-Hyun; Park, Jun-Bom; Kim, Dong Wuk | Kyungpook Natl Univ, Coll Pharm, Daegu 41566, South Korea; Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Daegu 41566, South Korea; Sahmyook Univ, Coll Pharm, Seoul 01795, South Korea | ; Giri, Bhupendra/GRR-3256-2022 | 57210211620; 57210213649; 57210209641; 57204042668; 36673633500; 57193445049 | giribhupen77@gmail.com;djstn0424@naver.com;kjw11156@naver.com;jelly_3004@naver.com;junji4@gmail.com;dkim17@knu.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 12 | 1 | SCIE | PHARMACOLOGY & PHARMACY | 2020 | 6.321 | 10.3 | 5.94 | 2025-06-25 | 81 | 90 | theophylline; hot-melt extrusion; fused deposition modeling 3D printing; gastro-retentive floating system; dissolution kinetics; controlled release | DRUG-DELIVERY SYSTEMS; SOLUTE RELEASE; CELLULOSE; POLYMERS; DESIGN; DOSAGE | Controlled release; Dissolution kinetics; Fused deposition modeling 3D printing; Gastro-retentive floating system; Hot-melt extrusion; Theophylline | theophylline; Article; controlled drug release; controlled study; differential scanning calorimetry; drug determination; drug diffusion; drug dosage form comparison; drug solubility; fused deposition modeling; hot melt extrusion; microtechnology; physical chemistry; scanning electron microscopy; tablet; tablet formulation; X ray powder diffraction | English | 2020 | 2020-01 | 10.3390/pharmaceutics12010077 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Hospital Volume Threshold Associated with Higher Survival after Endovascular Recanalization Therapy for Acute lschemic Stroke | Background and Purpose Endovascular recanalization therapy (ERT) is becoming increasingly important in the management of acute ischemic stroke (AIS). However, the hospital volume threshold for optimal ERT remains unknown. We investigated the relationship between hospital volume of ERT and risk-adjusted patient outcomes. Methods From the National Health Insurance claims data in Korea, 11,745 patients with AIS who underwent ERT from July 2011 to June 2016 in 111 hospitals were selected. We measured the hospital's ERT volume and patient outcomes, including the 30-day mortality, readmission, and postprocedural intracranial hemorrhage (ICH) rates. For each outcome measure, we constructed risk-adjusted prediction models incorporating demographic variables, the modified Charlson comorbidity index, and the stroke severity index (SSI), and validated them. Risk-adjusted outcomes of AIS cases were compared across hospital quartiles to confirm the volume-outcome relationship (VOR) in ERT. Spline regression was performed to determine the volume threshold. Results The mean AIS volume was 14.8 cases per hospital/year and the unadjusted means of mortality, readmission, and ICH rates were 11.6%, 4.6%, and 8.6%, respectively. The VOR was observed in the risk-adjusted 30-day mortality rate across all quartile groups, and in the ICH rate between the first and fourth quartiles (P<0.05). The volume threshold was 24 cases per year. Conclusions There was an association between hospital volume and outcomes, and the volume threshold in ERT was identified. Policies should be developed to ensure the implementation of the AIS volume threshold for hospitals performing ERT. | Shim, Dong-Hyun; Kim, Youngsoo; Roh, Jieun; Kang, Jongsoo; Park, Kyung-Pil; Cha, Jae-Kwan; Baik, Seung Kug; Kim, Yoon | Kyungpook Natl Univ Hosp, Dept Neurol, Daegu, South Korea; MH Yeonse Hosp, Dept Neurosurg, Chang Won, South Korea; Pusan Natl Univ, Sch Med, Yangsan Hosp, Dept Radiol, Yangsan, South Korea; Gyeongsang Natl Univ, Coll Med, Gyeongsang Natl Univ Hosp, Dept Neurol, Jinju, South Korea; Pusan Natl Univ, Sch Med, Yangsan Hosp, Dept Neurol, Yangsan, South Korea; Dong A Univ, Coll Med, Dong A Univ Hosp, Dept Neurol, Busan, South Korea; Seoul Natl Univ, Coll Med, Dept Hlth Policy & Management, 103 Daehak Ro, Seoul 03080, South Korea; Seoul Natl Univ, Med Res Ctr, Inst Hlth Policy & Management, Seoul, South Korea | ; Kim, Yoon/J-5423-2012 | 56779672200; 59837607100; 7102684066; 57202870606; 8361981900; 7202455743; 16642123700; 56088743900 | yoonkimmd@gmail.com; | JOURNAL OF STROKE | J STROKE | 2287-6391 | 2287-6405 | 22 | 1 | SCIE | CLINICAL NEUROLOGY;PERIPHERAL VASCULAR DISEASE | 2020 | 6.967 | 10.3 | 0.83 | 2025-06-25 | 20 | 17 | Stroke; Thrombectomy; Risk adjustment; Hospitals; high-volume; Quality and outcomes | ACUTE ISCHEMIC-STROKE; HEALTH-CARE PROFESSIONALS; INTRAVENOUS ALTEPLASE; OUTCOME RELATIONSHIP; THROMBECTOMY; MORTALITY; PERFORMANCE; ADJUSTMENT; STATEMENT; PERFECT | High-volume; Hospitals; Quality and outcomes; Risk adjustment; Stroke; Thrombectomy | aged; Article; blood clot lysis; brain hemorrhage; brain ischemia; cerebrovascular accident; clinical outcome; data base; endovascular recanalization therapy; female; follow up; hospital volume; human; major clinical study; male; mechanical thrombectomy; mortality; mortality rate; outcome assessment; recanalization; risk assessment; risk factor; stroke severity index; survival; survival analysis; validation process | English | 2020 | 2020-01 | 10.5853/jos.2019.00955 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | In Vitro Metabolism of DWP16001, a Novel Sodium-Glucose Cotransporter 2 Inhibitor, in Human and Animal Hepatocytes | DWP16001 is currently in a phase 2 clinical trial as a novel anti-diabetes drug for the treatment of type 2 diabetes by selective inhibition of sodium-glucose cotransporter 2. This in vitro study was performed to compare the metabolism of DWP16001 in human, dog, monkey, mouse, and rat hepatocytes, and the drug-metabolizing enzymes responsible for the metabolism of DWP16001 were characterized using recombinant human cytochrome 450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes expressed from cDNAs. The hepatic extraction ratio of DWP16001 in five species ranged from 0.15 to 0.56, suggesting that DWP16001 may be subject to species-dependent and weak-to-moderate hepatic metabolism. Five phase I metabolites (M1-M5) produced by oxidation as well as three DWP16001 glucuronides (U1-U3) and two hydroxy-DWP16001 (M1) glucuronides (U4, U5), were identified from hepatocytes incubated with DWP16001 by liquid chromatography-high resolution mass spectrometry. In human hepatocytes, M1, M2, M3, U1, and U2 were identified. Formation of M1 and M2 from DWP16001 was catalyzed by CYP3A4 and CYP2C19. M3 was produced by hydroxylation of M1, while M4 was produced by hydroxylation of M2; both hydroxylation reactions were catalyzed by CYP3A4. The formation of U1 was catalyzed by UGT2B7, but UGT1A4, UGT1A9, and UGT2B7 contributed to the formation of U2. In conclusion, DWP16001 is a substrate for CYP3A4, CYP2C19, UGT1A4, UGT1A9, and UGT2B7 enzymes. Overall, DWP16001 is weakly metabolized in human hepatocytes, but there is a potential for the pharmacokinetic modulation and drug-drug interactions, involved in the responsible metabolizing enzymes of DWP16001 in humans. | Kim, Ju-Hyun; Kim, Dong Kyun; Choi, Won-Gu; Ji, Hye-Young; Choi, Ji-Soo; Song, Im-Sook; Lee, Sangkyu; Lee, Hye Suk | Yeungnam Univ, Coll Pharm, Gyongsan 38541, South Korea; Catholic Univ Korea, Coll Pharm, Program Pharmac Based Future Pharm, PLUS Team Creat Leader BK21, Bucheon 14662, South Korea; Daewoong Pharmaceut Co Ltd, Inst Life Sci, Yongin 17028, South Korea; Kyungpook Natl Univ, Pharmaceut Sci Res Inst, Coll Pharm, Daegu 41566, South Korea | 55720031300; 55742880300; 57184763300; 57215682552; 57215689019; 7201564500; 57209046767; 35316111800 | jhkim@yu.ac.kr;kdk3124@catholic.ac.kr;cwg0222@catholic.ac.kr;hychi138@daewoong.co.kr;jschoi172@daewoong.co.kr;isssong@knu.ac.kr;sangkyu@knu.ac.kr;sianalee@catholic.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 12 | 9 | SCIE | PHARMACOLOGY & PHARMACY | 2020 | 6.321 | 10.3 | 1.19 | 2025-06-25 | 20 | 22 | DWP16001; SGLT2 inhibitor; metabolism; CYP; UGT | SELECTIVE INHIBITOR; SGLT2 INHIBITORS; PHARMACOKINETICS; DAPAGLIFLOZIN; CANAGLIFLOZIN; EMPAGLIFLOZIN; PHARMACODYNAMICS; SIMVASTATIN; PF-04971729; METFORMIN | CYP; DWP16001; Metabolism; SGLT2 inhibitor; UGT | 2 [7 chloro 6 (cyclopropylbenzyl) 2,3 dihydrobenzofuran 4 yl] 6 (hydroxymethyl)tetrahydro 2h pyran 3,4,5 triol; cytochrome P450 2C19; cytochrome P450 3A4; drug metabolite; dwp 16001; glucuronosyltransferase 1A4; glucuronosyltransferase 1A9; glucuronosyltransferase 2B7; recombinant enzyme; sodium glucose cotransporter 2 inhibitor; unclassified drug; animal cell; Article; catalysis; controlled study; dog; drug clearance; drug half life; drug hydroxylation; drug metabolism; drug oxidation; enzyme substrate; Haplorhini; human; human cell; in vitro study; liver cell; liver metabolism; liver microsome; mouse; nonhuman; protein expression; rat; species comparison | English | 2020 | 2020-09 | 10.3390/pharmaceutics12090865 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Inhibitory Effect of AB-PINACA, Indazole Carboxamide Synthetic Cannabinoid, on Human Major Drug-Metabolizing Enzymes and Transporters | Indazole carboxamide synthetic cannabinoid, AB-PINACA, has been placed into Schedule I of the Controlled Substances Act by the US Drug Enforcement Administration since 2015. Despite the possibility of AB-PINACA exposure in drug abusers, the interactions between AB-PINACA and drug-metabolizing enzymes and transporters that play crucial roles in the pharmacokinetics and efficacy of various substrate drugs have not been investigated. This study was performed to investigate the inhibitory effects of AB-PINACA on eight clinically important human major cytochrome P450s (CYPs) and six uridine 5 '-diphospho-glucuronosyltransferases (UGT) in human liver microsomes and the activities of six solute carrier transporters and two efflux transporters in transporter-overexpressing cells. AB-PINACA reversibly inhibited the metabolic activities of CYP2C8 (K-i, 16.9 mu M), CYP2C9 (K-i, 6.7 mu M), and CYP2C19 (K-i, 16.1 mu M) and the transport activity of OAT3 (K-i, 8.3 mu M). It exhibited time-dependent inhibition on CYP3A4 (K-i, 17.6 mu M; k(inact), 0.04047 min(-1)). Other metabolizing enzymes and transporters such as CYP1A2, CYP2A6, CYP2B6, CYP2D6, UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, OAT1, OATP1B1, OATP1B3, OCT1, OCT2, P-glycoprotein, and BCRP, exhibited only weak interactions with AB-PINACA. These data suggest that AB-PINACA can cause drug-drug interactions with CYP3A4 substrates but that the significance of drug interactions between AB-PINACA and CYP2C8, CYP2C9, CYP2C19, or OAT3 substrates should be interpreted carefully. | Park, Eun Jeong; Park, Ria; Jeon, Ji-Hyeon; Cho, Yong-Yeon; Lee, Joo Young; Kang, Han Chang; Song, Im-Sook; Lee, Hye Suk | Catholic Univ Korea, Coll Pharm, Bucheon 14662, South Korea; Kyungpook Natl Univ, Coll Pharm, Daegu 41566, South Korea; Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Daegu 41566, South Korea | ; Cho, Yong-Yeon/AAD-4263-2020; Kang, Han/I-5999-2019 | 58333586800; 57215577826; 57204685946; 55472207900; 57215684977; 36150873700; 7201564500; 35316111800 | enddl0818@catholic.ac.kr;hyacinthy7@catholic.ac.kr;kei7016@naver.com;yongyeon@catholic.ac.kr;joolee@catholic.ac.kr;hckang@catholic.ac.kr;isssong@knu.ac.kr;sianalee@catholic.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 12 | 11 | SCIE | PHARMACOLOGY & PHARMACY | 2020 | 6.321 | 10.3 | 0.69 | 2025-06-25 | 10 | 9 | AB-PINACA; drug interaction; drug-metabolizing enzyme; drug transporter | ORGANIC ANION TRANSPORTERS; CATION TRANSPORTERS; PHARMACOKINETICS; CYTOCHROME-P450; FUBINACA; CHMINACA | AB-PINACA; Drug interaction; Drug transporter; Drug-metabolizing enzyme | ab pinaca; ABC transporter subfamily B; breast cancer resistance protein; cannabinoid derivative; carrier protein; cytochrome P450; cytochrome P450 1A2; cytochrome P450 2A6; cytochrome P450 2B6; cytochrome P450 2C19; cytochrome P450 2C8; cytochrome P450 2C9; cytochrome P450 2D6; cytochrome P450 3A4; glucuronosyltransferase; glucuronosyltransferase 1A1; glucuronosyltransferase 1A3; glucuronosyltransferase 1A4; glucuronosyltransferase 1A6; glucuronosyltransferase 1A9; glucuronosyltransferase 2B7; indazole carboxamide synthetic cannabinoid; indazole derivative; organic anion transporter 1; organic cation transporter 1; organic cation transporter 2; solute carrier organic anion transporter 1B1; solute carrier organic anion transporter 1B3; unclassified drug; Article; concentration response; controlled study; drug interaction; drug protein binding; enzyme activity; enzyme inhibition; enzyme kinetics; enzyme substrate; female; human; human cell; IC50; liver microsome; male; molecular docking; protein function | English | 2020 | 2020-11 | 10.3390/pharmaceutics12111036 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Editorial Material | Management of Acute Stroke Patients Amid the Coronavirus Disease 2019 Pandemic: Scientific Statement of the Korean Stroke Society | Kim, Beom Joon; Kim, Eu Suk; Shin, Myoung Jin; Kim, Hong Bin; Lee, Hee Young; Hong, Keun-Sik; Park, Hong-Kyun; Lee, Jun; Sohn, Sung-Il; Hwang, Yang-Ha; Ko, Sang-Bae; Park, Jong-Moo; Rha, Joung-Ho; Kwon, Sun U.; Kim, Jong S.; Heo, Ji Hoe; Lee, Byung Chul; Yoon, Byung-Woo; Bae, Hee-Joon | Seoul Natl Univ, Bundang Hosp, Dept Neurol, Coll Med, 82 Gumi Ro 173beon Qil, Seongnam 13620, South Korea; Seoul Natl Univ, Bundang Hosp, Gyunggi Reg Cardiocerebrovasc Ctr, Coll Med, Seongnam, South Korea; Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Seongnam, South Korea; Seoul Natl Univ, Bundang Hosp, Infect Control Off, Seongnam, South Korea; Seoul Natl Univ, Bundang Hosp, Infect Control Off, Seongnam, South Korea; Seoul Natl Univ, Bundang Hosp, Ctr Publ Hlth, Seongnam, South Korea; Gyeonggi Infect Dis Control Ctr, Seongnam, South Korea; Inje Univ, Ilsan Paik Hosp, Coll Med, Dept Neurol, Goyang, South Korea; Yeungnam Univ Hosp, Dept Neurol, Daegu, South Korea; Keimyung Univ, Dongsan Med Ctr, Dept Neurol, Daegu, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Neurol, Daegu, South Korea; Seoul Natl Univ Hosp, Dept Neurol, Seoul, South Korea; Eulji Univ, Sch Med, Eulji Gen Hosp, Dept Neurol, Seoul, South Korea; Inha Univ Hosp, Dept Neurol, Incheon, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Dept Neurol, Seoul, South Korea; Yonsei Univ, Coll Med, Severance Hosp, Dept Neurol, Seoul, South Korea; Hallym Univ, Sacred Heart Hosp, Hallym Neurol Inst, Dept Neurol, Anyang, South Korea | ; Kim, Beom Joon/C-2904-2011; lee, hy/GRS-0797-2022; Kim, Eu/J-5424-2012; Kim, Hee/AAU-6368-2021; Yoon, Byung/J-5557-2012; Kim, Hong Bin/J-5452-2012; HWANG, Yang-Ha/F-3068-2013; Kim, Seung/N-5248-2019 | 56415337700; 22938086900; 54781830800; 35307429400; 7501482409; 7402515553; 58205849100; 55894819500; 36479287000; 7402311308; 7403326154; 8407334400; 6701393879; 7402624264; 57222278740; 34869576000; 57201966362; 13310144900; 7103223963 | braindoc@snu.ac.kr; | JOURNAL OF STROKE | J STROKE | 2287-6391 | 2287-6405 | 22 | 2 | SCIE | CLINICAL NEUROLOGY;PERIPHERAL VASCULAR DISEASE | 2020 | 6.967 | 10.3 | 1.56 | 2025-06-25 | 7 | 7 | angiography; blood clot lysis; cerebrovascular accident; coronavirus disease 2019; coughing; diarrhea; dizziness; dyspnea; emergency ward; endotracheal intubation; eye protection; fever; headache; heart failure; hospital care; hospital personnel; human; hypercoagulability; Note; pandemic; pneumonia; quarantine; recanalization; risk factor; Severe acute respiratory syndrome coronavirus 2; stroke unit; thorax pain; virus myocarditis; virus shedding; virus transmission; vomiting | English | 2020 | 2020-05 | 10.5853/jos.2020.01291 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||||
| ○ | ○ | Article | Molecular characteristics of fluoroquinolone-resistant avian pathogenic Escherichia coli isolated from broiler chickens | Avian pathogenic Escherichia coli (APEC) is a major pathogen in the poultry industry worldwide including Korea. In this study, the phenotypic and genotypic characteristics of 33 fluoroquinolone (FQ)-resistant APEC isolates from broilers were analyzed. All FQ-resistant APEC isolates showed amino acid exchanges at both gyrA and parC and high minimal inhibitory concentrations for FQs. A total of 11 (33.3%) isolates were positive for the plasmid-mediated quinolone resistance (PMQR) genes, qnrA(8 isolates) and qnrS (3 isolates), and showed multidrug resistance. Among the 11 PMQR-positive isolates, 1 and 2 isolates carried bla(CTX-1) and bla(CTX-15), respectively, as extended-spectrum beta-lactamase (ESBL) producers, and the non-ESBL gene, bla(TEM-1), was found in 4 isolates. Among 3 aminoglycoside-resistant isolates, aac(3)-II was only detected in 1 isolate. All 8 APEC isolates with resistance to tetracycline carried the tetA gene. Overall, 6 of the 7 trimethoprim-sulfamethoxazole-resistant isolates carried the sul1 or sul2 genes, while only 2 of the 8 chloramphenicol-resistant isolates carried the catA1 gene. Although 9 isolates carried class I integrons, only 4 isolates carried the gene cassettes dfrA12-aadA2 (2 isolates), dfrA17-aadA5 (1 isolate), extX-psp-aadA2 (1 isolate), and dfrA27 (1 isolate). The most common plasmid replicon was FIB (8 isolates, 72.7%), followed by K/B (4 isolates, 36.4%). Antimicrobial resistance monitoring and molecular analysis of APEC should be performed continuously to surveil the transmission between poultry farms. | Yoon, Mi Young; Kim, Yeong Bin; Ha, Jong Su; Seo, Kwang Won; Noh, Eun Bi; Son, Se Hyun; Lee, Young Ju | Samhwa GPS Breeding Agri Inc, Qual Management Dept, Hongseong Gun 32291, Chung Nam, South Korea; Kyungpook Natl Univ, Coll Vet Med, Daegu 41566, South Korea; Kyungpook Natl Univ, Zoonoses Res Inst, Daegu 41566, South Korea; Mississippi State Univ, Coll Vet Med, Dept Basic Sci, Mississippi State, MS 39762 USA | 57214463716; 57200044764; 56180548400; 57203233812; 57209844683; 57209841240; 56612134500 | youngju@knu.ac.kr; | POULTRY SCIENCE | POULTRY SCI | 0032-5791 | 1525-3171 | 99 | 7 | SCIE | AGRICULTURE, DAIRY & ANIMAL SCIENCE | 2020 | 3.352 | 10.3 | 1.87 | 2025-06-25 | 16 | 16 | antimicrobial-resistant gene; APEC; broiler; multidrug resistance; plasmid-mediated quinolone resistance | MEDIATED QUINOLONE RESISTANCE; CLASS 1 INTEGRONS; ANTIBIOTIC-RESISTANCE; ANTIMICROBIAL RESISTANCE; BETA-LACTAMASES; GENES; VIRULENCE; STRAINS; COLIBACILLOSIS; IDENTIFICATION | antimicrobial-resistant gene; APEC; broiler; multidrug resistance; plasmid-mediated quinolone resistance | Animals; Anti-Bacterial Agents; Chickens; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Poultry Diseases; Republic of Korea; antiinfective agent; quinolone derivative; animal; bird disease; chicken; drug effect; Escherichia coli; Escherichia coli infection; genetics; microbiology; multidrug resistance; South Korea; veterinary medicine | English | 2020 | 2020-07 | 10.1016/j.psj.2020.03.029 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Molecular characteristics of optrA-carrying Enterococcus faecalis from chicken meat in South Korea | The purpose of this study was to identify the genetic environment of optrA gene in linezolid (LZD)-resistant Enterococcus faecalis from chicken meat and to describe the probable mechanism of dissemination of the optrA gene through plasmid or chromosomal integration. Whole genome sequencing and analysis revealed that all 3 E. faecalis isolates confirmed as LZDand chloramphenicol-resistant carried fexA adjacent to the optrA gene as well as a variety of resistance genes for macrolides, tetracyclines, and amino glycosides, simultaneously. But, the other genes conferring LZD resistance, cfr and poxtA, were not detected in those strains. Two isolates harboring the optrA gene in their chromosomal DNA showed >99% similarity in arrangement to the transposon Tn6674 and the transposase genes, tnpA, tnpB, and tnpC and were located in the first open reading frame for transposase. One isolate harboring an optrA-carrying plasmid also showed >99% similarity with the previously reported pE439 plasmid but had 2 amino acid changes (Thr96Lys and Tyr160Asp) and a higher minimum inhibitory concentration against LZD of 16 mg/L than that of pE439 (8 mg/L). Mobile genetic elements such as transposons or plasmids flanking the optrA gene conduct a crucial role in the dissemination of antimicrobial resistance genes. Further investigations are required to identify the way by which optrA is integrated into chromosomal DNA and plasmids. | Yoon, Sunghyun; Son, Se Hyun; Kim, Yeong Bin; Seo, Kwang Won; Lee, Young Ju | Kyungpook Natl Univ, Coll Vet Med, Daegu 41566, South Korea; Kyungpook Natl Univ, Zoonoses Res Inst, Daegu 41566, South Korea; Anim & Plant Quarantine Agcy, Anim Dis Diagnost Div, Gimcheon Si 39660, Gyeongsangbuk D, South Korea; Mississippi State Univ, Dept Basic Sci, Coll Vet Med, Mississippi State, MS 39762 USA | Yoon, Sunghyun/AAL-4806-2021 | 57216037473; 57209841240; 57200044764; 57203233812; 56612134500 | youngju@knu.ac.kr; | POULTRY SCIENCE | POULTRY SCI | 1525-3171 | 99 | 12 | SCIE | AGRICULTURE, DAIRY & ANIMAL SCIENCE | 2020 | 3.352 | 10.3 | 1.4 | 2025-06-25 | 15 | 15 | optrA; fexA; Enterococcus faecalis; antimicrobial resistance; linezolid-resistance | RESISTANCE GENE OPTRA; ANTIBIOTIC-RESISTANCE; LINEZOLID RESISTANCE; ANNUAL APPRAISAL; OXAZOLIDINONES; PHENICOLS; FAECIUM; POTENCY; ORIGIN | antimicrobial resistance; Enterococcus faecalis; fexA; linezolid-resistance; optrA | Animals; Anti-Bacterial Agents; Chickens; Drug Resistance, Bacterial; Enterococcus faecalis; Genes, Bacterial; Meat; Microbial Sensitivity Tests; Republic of Korea; antiinfective agent; animal; antibiotic resistance; bacterial gene; chicken; drug effect; Enterococcus faecalis; genetics; meat; microbial sensitivity test; microbiology; South Korea; veterinary medicine | English | 2020 | 2020-12 | 10.1016/j.psj.2020.08.062 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Molecular characterization of avian pathogenic Escherichia coli from broiler chickens with colibacillosis | Avian pathogenic Escherichia coli (APEC) causes extensive mortality in poultry flocks, leading to extensive economic losses. The aim of this study was to investigate the phenotypic and genotypic characteristics and antimicrobial resistance of recent APEC isolates. Of the 79 APEC isolates, the most predominant serogroup was O78 (16 isolates, 20.3%), followed by O2 (7 isolates, 8.9%) and O53 (7 isolates, 8.9%). Thirty-seven (46.8%) and six (7.6%) of the isolates belonged to phylogenetic groups D and B2, respectively, and presented as virulent extraintestinal E. coli. Among 5 analyzed virulence genes, the highest frequency was observed in hlyF (74 isolates, 93.7%), followed by iutA (72 isolates, 91.9%) gene. The distribution of the iss gene was significantly different between groups A/B1 and B2/D (P < 0.05). All group B2 isolates carried all 5 virulence genes. APEC isolates showed high resistance to ampicillin (83.5%), nalidixic acid (65.8%), tetracycline (64.6%), cephalothin (46.8%), and ciprofloxacin (46.8%). The beta-lactamases-encoding genes bla(TEM-1 ) (23 isolates, 29.1%), bla(CTX-M-1) (4 isolates, 5.1%), and bla(CTX-M-15) (3 isolates, 3.8%); the aminoglycoside-modifying enzyme gene aac(3)-II (4 isolates, 5.1%); and the plasmid-mediated quinolone genes qnrA (10 isolates, 12.7%) and qnrS (2 isolates, 2.5%) were identified in APEC isolates. The tetA (37 isolates, 46.8%) and sul2 (20 isolates, 25.3%) were the most prevalent among tetracycline and sulfonamide resistant isolates, respectively. This study indicates that APEC isolates harbor a variety of virulence and resistance genes; such genes are often associated with plasmids that facilitate their transmission between bacteria and should be continuously monitored to track APEC transmission in poultry farms. | Kim, Yeong Bin; Yoon, Mi Young; Ha, Jong Su; Seo, Kwang Won; Noh, Eun Bi; Son, Se Hyun; Lee, Young Ju | Kyungpook Natl Univ, Coll Vet Med, Daegu 41566, South Korea; Samhwa GPS Breeding Agri Inc, Hongseong 32291, South Korea; Mississippi State Univ, Coll Vet Med, Dept Basic Sci, Mississippi State, MS 39762 USA | 57200044764; 57214463716; 56180548400; 57203233812; 57209844683; 57209841240; 56612134500 | youngju@knu.ac.kr; | POULTRY SCIENCE | POULTRY SCI | 1525-3171 | 99 | 2 | SCIE | AGRICULTURE, DAIRY & ANIMAL SCIENCE | 2020 | 3.352 | 10.3 | 10.13 | 2025-06-25 | 97 | 100 | avian pathogenic Escherichia coli; antimicrobial resistance; phylogenetic group; broilers | MEDIATED QUINOLONE RESISTANCE; M-BETA-LACTAMASES; ANTIBIOTIC-RESISTANCE; ANTIMICROBIAL RESISTANCE; GENOTYPIC CHARACTERIZATION; VIRULENCE; GENES; STRAINS; INTEGRONS; IDENTIFICATION | antimicrobial resistance; avian pathogenic Escherichia coli; broilers; phylogenetic group | Animals; Chickens; Drug Resistance, Microbial; Escherichia coli; Escherichia coli Infections; Genotype; Phenotype; Poultry Diseases; Republic of Korea; Virulence; animal; antibiotic resistance; bird disease; chicken; drug effect; Escherichia coli; Escherichia coli infection; genetics; genotype; microbiology; pathogenicity; phenotype; South Korea; veterinary medicine; virulence | English | 2020 | 2020-02 | 10.1016/j.psj.2019.10.047 | 바로가기 | 바로가기 | 바로가기 | 바로가기 |
페이지 이동: